Search

Sanofi Pledges $125M to Denali in Pact for Neuro, Inflammation Drugs

SANOFI PLEDGES $125M TO DENALI IN PACT FOR NEURO, INFLAMMATION DRUGS

Sanofi sees potential in two early-stage Denali Therapeutics drugs as a way to reduce inflammation in the brain and throughout the...

 
 
 
Bio Roundup: Prices on TV, Novartis Hearts Radio, Warp Drive's End

BIO ROUNDUP: PRICES ON TV, NOVARTIS HEARTS RADIO, WARP DRIVE'S END

Two new battlegrounds emerged this week in the nation's ongoing drug pricing debate. The first involved television: The federal government...

BIO Investor Forum Explores “Digiceuticals” as a New Class of FDA-Approved Therapeutics

BIO INVESTOR FORUM EXPLORES “DIGICEUTICALS” AS A NEW CLASS OF FDA-APPROVED THERAPEUTICS

Within the past year, the FDA has launched a provider pre-certification program as a pilot to manage the expansion of “digiceuticals”...

 
 
 
Warp Drive's Odyssey Ends with a Buyout-By Revolution, Not Sanofi

WARP DRIVE'S ODYSSEY ENDS WITH A BUYOUT-BY REVOLUTION, NOT SANOFI

Warp Drive Bio started up in 2012 with a potential buyer, Sanofi, already in place. Six years later the Cambridge, MA, company is being...

HEAD OF ENGINEERING & MAINTENANCE / RESPONSABLE INGÉNIERIE INDUSTRIELLE ET MAINTENANCE

At Sanofi diversity and inclusion is foundational to how we operate and embedded in our Core Values. We recognize to truly tap into...

 
 
 
Bio Roundup: Nobel Prizes, Duchenne Steps, Guardant's IPO & More

BIO ROUNDUP: NOBEL PRIZES, DUCHENNE STEPS, GUARDANT'S IPO & MORE

Cancer immunotherapy is all the rage these days. The idea of harnessing the immune system to treat cancer has sparked billions of dollars...

 
 
 
Principia Sets IPO Terms as It Eyes Late-Stage Studies for Lead Drug

PRINCIPIA SETS IPO TERMS AS IT EYES LATE-STAGE STUDIES FOR LEAD DRUG

Principia Biopharma plans to sell 4.6 million shares priced between $15 and $17 apiece when the rare disease drug developer makes its...

 
 
 
Bio Roundup: Drug Prices, CRISPR Caveats, Rubius IPO Pop & More

BIO ROUNDUP: DRUG PRICES, CRISPR CAVEATS, RUBIUS IPO POP & MORE

After nearly two years of all smoke, no fire around President Trump's promise to curtail drug prices, there's finally some glimmer...

EVOTEC SEALS DEAL FOR SANOFI'S INFECTIOUS DISEASE UNIT

Evotec has wrapped up a deal for Sanofi's infectious disease unit. The agreement sees Sanofi transfer 100 employees, more than 10 drug...

 
 
 
Pharma giants like Novartis, Pfizer, and Sanofi are getting serious about a cutting edge therapy that changes human genes

PHARMA GIANTS LIKE NOVARTIS, PFIZER, AND SANOFI ARE GETTING SERIOUS ABOUT A CUTTING EDGE THERAPY THAT CHANGES HUMAN GENES

Pharma is getting serious about gene therapy, one-time treatments that modify genes to potentially cure serious diseases. Novartis...

 
 
 
Ambien Maker Sanofi to Roseanne Barr: No, Our Sleeping Pill Doesn't Cause Racism

AMBIEN MAKER SANOFI TO ROSEANNE BARR: NO, OUR SLEEPING PILL DOESN'T CAUSE RACISM

Roseanne Barr just got some epic Twitter shade from... one of the world's largest pharmaceutical companies. French drug giant Sanofi...

Roseanne blames Ambien for her racist tweet - but Ambien-maker says racism 'is not a known side effect' of its medications

ROSEANNE BLAMES AMBIEN FOR HER RACIST TWEET - BUT AMBIEN-MAKER SAYS RACISM 'IS NOT A KNOWN SIDE EFFECT' OF ITS MEDICATIONS

ABC Roseanne, the star of the now-canceled eponymous sitcom "Roseanne," blamed Ambien for her tweet comparing former Obama advisor...

 
 
 
Ambien maker trolls Roseanne Barr on Twitter

AMBIEN MAKER TROLLS ROSEANNE BARR ON TWITTER

"While all pharmaceutical treatments have side effects, racism is not a known side effect of any Sanofi medication,” the pharmaceutical...

LOOKING TO UNSEAT SANOFI AND SHIRE DRUGS, ATLAS GENE THERAPY STARTUP AVROBIO FILES FOR $86M IPO

Avrobio has filed for an $86.25 million IPO. The offering would give the Atlas Venture-backed startup the means to run clinical trials...